your welcome mirror, yes things are really slow on in here and this company is for sure a sleeper (for now) cant think of any long term issues at this point other than the need for cash down the road. dont think its gonna be an issue near term. we should get an update on the glucagon program in the next earnings call, but, that is probably 9 months to a year from a trial. all eyes are on phase 2 results. i think the stock gets above 3 soon and stays there this time.
edikagbr, havent heard from you in a while. interesting take on novo and lilly. we will find out in a few weeks.